Vorinostat/SAHA-induced apoptosis in malignant mesothelioma is FLIP/caspase 8-dependent and HR23B-independent

European Journal of Cancer

Volumn 48, Issue 7, 2012, Pages 1096-1107

  Hurwitz, Jane L ^a   Stasik, Izabela ^a   Kerr, Emma M ^a   Holohan, Caitriona ^a   Redmond, Kelly M ^a   McLaughlin, Kirsty M ^a   Busacca, Sara ^a   Barbone, Dario ^b   Broaddus, V Courtney ^b   Gray, Steven G ^c   O'Byrne, Ken J ^c   Johnston, Patrick G ^a   Fennell, Dean A ^a   Longley, Daniel B ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c ST JAMES S HOSPITAL   (Ireland)

Author keywords

Caspase 8; FLIP; HDAC inhibitors; Mesothelioma; SAHA Vorinostat

Indexed keywords

BIOLOGICAL MARKER; CASPASE 8; CISPLATIN; FLICE INHIBITORY PROTEIN; VORINOSTAT;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; DOWN REGULATION; DRUG EFFECT; DRUG POTENCY; DRUG POTENTIATION; MALIGNANT MESOTHELIOMA; PRIORITY JOURNAL;

APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CASP8 AND FADD-LIKE APOPTOSIS REGULATING PROTEIN; CASPASE 8; CELL LINE, TUMOR; DNA REPAIR ENZYMES; DNA-BINDING PROTEINS; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; MALE; MESOTHELIOMA; PLEURAL NEOPLASMS; RNA INTERFERENCE; SPHEROIDS, CELLULAR;

EID: 84859479271     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2011.11.009     Document Type: Article

References (51)

1. M. Ray, and H.L. Kindler Malignant pleural mesothelioma: an update on biomarkers and treatment Chest 136 2009 888 896
2. D.A. Fennell, G. Gaudino, and K.J. O'Byrne Advances in the systemic therapy of malignant pleural mesothelioma Nat Clin Pract Oncol 5 2008 136 147
3. S.S. Ramalingam, and C.P. Belani Recent advances in the treatment of malignant pleural mesothelioma J Thorac Oncol 3 2008 1056 1064
4. P.K. Paik, and L.M. Krug Histone deacetylase inhibitors in malignant pleural mesothelioma: preclinical rationale and clinical trials J Thorac Oncol 5 2010 275 279
5. W.K. Kelly, O.A. O'Connor, and L.M. Krug Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer J Clin Oncol 23 2005 3923 3931
6. W.K. Kelly, V.M. Richon, and O. O'Connor Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously Clin Cancer Res 9 2003 3578 3588
7. D.A. Fennell, A. Parmar, and J. Shamash Statistical validation of the EORTC prognostic model for malignant pleural mesothelioma based on three consecutive phase II trials J Clin Oncol 23 2005 184 189
8. D.A. Fennell, and R.M. Rudd Defective core-apoptosis signalling in diffuse malignant pleural mesothelioma: opportunities for effective drug development Lancet Oncol 5 2004 354 362
9. A. Ashkenazi, and V.M. Dixit Apoptosis control by death and decoy receptors Curr Opin Cell Biol 11 1999 255 260
10. S. Van Schaeybroeck, D.M. Kelly, and J. Kyula Src and ADAM-17-mediated shedding of transforming growth factor-alpha is a mechanism of acute resistance to TRAIL Cancer Res 68 2008 8312 8321
11. A. Krueger, S. Baumann, and P.H. Krammer FLICE-inhibitory proteins: regulators of death receptor-mediated apoptosis Mol Cell Biol 21 2001 8247 8254
12. M.R. Rippo, S. Moretti, and S. Vescovi FLIP overexpression inhibits death receptor-induced apoptosis in malignant mesothelial cells Oncogene 23 2004 7753 7760
13. T.R. Wilson, K.M. McLaughlin, and M. McEwan C-FLIP: a key regulator of colorectal cancer cell death Cancer Res 67 2007 5754 5762
14. T.R. Wilson, K.M. Redmond, and K. McLaughlin Procaspase 8 overexpression in non-small cell lung cancer promotes apoptosis induced by FLIP silencing Cell Death Differ 16 2009 1352 1361
15. W.S. Xu, R.B. Parmigiani, and P.A. Marks Histone deacetylase inhibitors: molecular mechanisms of action Oncogene 26 2007 5541 5552
16. J.L. Aron, M.R. Parthun, and G. Marcucci Depsipeptide (FR901228) induces histone acetylation and inhibition of histone deacetylase in chronic lymphocytic leukemia cells concurrent with activation of caspase 8-mediated apoptosis and down-regulation of c-FLIP protein Blood 102 2003 652 658
17. M. Schuchmann, H. Schulze-Bergkamen, and B. Fleischer Histone deacetylase inhibition by valproic acid down-regulates c-FLIP/CASH and sensitizes hepatoma cells towards CD95- and TRAIL receptor-mediated apoptosis and chemotherapy Oncol Rep 15 2006 227 230
18. K. Watanabe, K. Okamoto, and S. Yonehara Sensitization of osteosarcoma cells to death receptor-mediated apoptosis by HDAC inhibitors through downregulation of cellular FLIP Cell Death Differ 12 2005 10 18
19. S. Fotheringham, M.T. Epping, and L. Stimson Genome-wide loss-of-function screen reveals an important role for the proteasome in HDAC inhibitor-induced apoptosis Cancer Cell 15 2009 57 66
20. D.B. Longley, T.R. Wilson, and M. McEwan c-FLIP inhibits chemotherapy-induced colorectal cancer cell death Oncogene 25 2006 838 848
21. D. Barbone, T.M. Yang, and J.R. Morgan Mammalian target of rapamycin contributes to the acquired apoptotic resistance of human mesothelioma multicellular spheroids J Biol Chem 283 2008 13021 13030
22. T.D. Schmittgen, and K.J. Livak Analyzing real-time PCR data by the comparative C(T) method Nat Protoc 3 2008 1101 1108
23. C.S. Mitsiades, N.S. Mitsiades, and C.J. McMullan Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications Proc Natl Acad Sci USA 101 2004 540 545
24. D. Carlisi, M. Lauricella, and A. D'Anneo The histone deacetylase inhibitor suberoylanilide hydroxamic acid sensitises human hepatocellular carcinoma cells to TRAIL-induced apoptosis by TRAIL-DISC activation Eur J Cancer 45 2009 2425 2438
25. C.S. Mitsiades, V. Poulaki, and C. McMullan Novel histone deacetylase inhibitors in the treatment of thyroid cancer Clin Cancer Res 11 2005 3958 3965
26. O. Khan, S. Fotheringham, and V. Wood HR23B is a biomarker for tumor sensitivity to HDAC inhibitor-based therapy Proc Natl Acad Sci USA 107 2010 6532 6537
27. K. Sugasawa, J.M. Ng, and C. Masutani Two human homologs of Rad23 are functionally interchangeable in complex formation and stimulation of XPC repair activity Mol Cell Biol 17 1997 6924 6931
28. L. Chen, and K. Madura Rad23 promotes the targeting of proteolytic substrates to the proteasome Mol Cell Biol 22 2002 4902 4913
29. Y. Soini, K. Kahlos, and R. Sormunen Activation and relocalization of caspase 3 during the apoptotic cascade of human mesothelioma cells APMIS 113 2005 426 435
30. A. Golks, D. Brenner, and P.H. Krammer The c-FLIP-NH2 terminus (p22-FLIP) induces NF-kappaB activation J Exp Med 203 5 2006 1295 1305
31. R.S. Herbst, S.G. Eckhardt, and R. Kurzrock Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer J Clin Oncol 10 28 2010 2839 2846
32. S.J. Hotte, H.W. Hirte, and E.X. Chen A phase 1 study of mapatumumab (fully human monoclonal antibody to TRAIL-R1) in patients with advanced solid malignancies Clin Cancer Res 14 2008 3450 3455
33. T. Trarbach, M. Moehler, and V. Heinemann Phase II trial of mapatumumab, a fully human agonistic monoclonal antibody that targets and activates the tumour necrosis factor apoptosis-inducing ligand receptor-1 (TRAIL-R1), in patients with refractory colorectal cancer Br J Cancer 102 2010 506 512
34. M. Bagnoli, F. Ambrogi, and S. Pilotti c-FLIPL expression defines two ovarian cancer patient subsets and is a prognostic factor of adverse outcome Endocr Relat Cancer 16 2 2009 443 453
35. K.M. Rogers, M. Thomas, and L. Galligan Cellular FLICE-inhibitory protein regulates chemotherapy-induced apoptosis in breast cancer cells Mol Cancer Ther 6 5 2007 1544 1551
36. X. Zhang, T.G. Jin, and H. Yang Persistent c-FLIP(L) expression is necessary and sufficient to maintain resistance to tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in prostate cancer Cancer Res 64 19 2004 7086 7091
37. W.S. Xu, R.B. Parmigiani, and P.A. Marks Histone deacetylase inhibitors: molecular mechanisms of action Oncogene 26 37 2007 5541 5552
38. B.S. Mann, J.R. Johnson, and M.H. Cohen FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma Oncologist 12 10 2007 1247 1252
39. W. Xu, L. Ngo, and G. Perez Intrinsic apoptotic and thioredoxin pathways in human prostate cancer cell response to histone deacetylase inhibitor Proc Natl Acad Sci USA 103 2006 15540 15545
40. J. Neuzil, E. Swettenham, and N. Gellert Sensitization of mesothelioma to TRAIL apoptosis by inhibition of histone deacetylase: role of Bcl-xL down-regulation Biochem Biophys Res Commun 314 2004 186 191
41. F. Vandermeers, P. Hubert, and P. Delvenne Valproate, in combination with pemetrexed and cisplatin, provides additional efficacy to the treatment of malignant mesothelioma Clin Cancer Res 15 2009 2818 2828
42. M.R. Abedini, Q. Qiu, and X. Yan Possible role of FLICE-like inhibitory protein (FLIP) in chemoresistant ovarian cancer cells in vitro Oncogene 23 2004 6997 7004
43. P. Kamarajan, N.K. Sun, and C.C. Chao Up-regulation of FLIP in cisplatin-selected HeLa cells causes cross-resistance to CD95/Fas death signalling Biochem J 376 Pt. 1 2003 253 260
44. J. Shen, C. Huang, and L. Jiang Enhancement of cisplatin induced apoptosis by suberoylanilide hydroxamic acid in human oral squamous cell carcinoma cell lines Biochem Pharmacol 73 2007 1901 1909
45. S.S. Ramalingam, R.A. Parise, and R.K. Ramanathan Phase I and pharmacokinetic study of vorinostat, a histone deacetylase inhibitor, in combination with carboplatin and paclitaxel for advanced solid malignancies Clin Cancer Res 13 2007 3605 3610
46. A.J. Frew, R.K. Lindemann, and B.P. Martin Combination therapy of established cancer using a histone deacetylase inhibitor and a TRAIL receptor agonist Proc Natl Acad Sci USA 105 2008 11317 11322
47. L. Stimson, V. Wood, and O. Khan HDAC inhibitor-based therapies and haematological malignancy Ann Oncol 20 2009 1293 1302
48. M. Dejligbjerg, M. Grauslund, and I.J. Christensen Identification of predictive biomarkers for the histone deacetylase inhibitor belinostat in a panel of human cancer cell lines Cancer Biomarkers 4 2008 101 109
49. A. Miyanaga, A. Gemma, and R. Noro Antitumor activity of histone deacetylase inhibitors in non-small cell lung cancer cells: development of a molecular predictive model Mol Cancer Ther 7 2008 1923 1930
50. L.M. Krug, H. Kindler, and H. Calvert Vorinostat in patients with advanced malignant pleural mesothelioma who have failed prior pemetrexed and either cisplatin or carboplatin therapy: a phase III, randomized, double-blind, placebo-controlled trial Eur J Cancer 47 Suppl. 2, Late Breaking and Best of 2011 EMCC Abstracts 2011 2 3
51. T.S. Mok, Y.L. Wu, and S. Thongprasert Gefitinib or carboplatin- paclitaxel in pulmonary adenocarcinoma N Engl J Med 361 2009 947 957